| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.080 | Biomarker | group | BEFREE | No genetic associations with mepolizumab efficacy in COPD with peripheral blood eosinophilia. | 31295674 | 2019 | ||||
|
0.080 | GeneticVariation | group | BEFREE | The main objective of this study is to investigate readmission outcomes associated with blood eosinophilia following severe COPD exacerbation in patients with infrequent COPD hospitalizations. | 30319252 | 2019 | ||||
|
0.080 | Biomarker | group | BEFREE | ACO was diagnosed in a cohort of COAD patients in those patients with COPD who were either diagnosed with current asthma or showed significant blood eosinophilia (≥300cells/μl) and/or a very positive bronchodilator response (>400ml and >15% in FEV1). | 29229474 | 2018 | ||||
|
0.080 | GeneticVariation | group | BEFREE | Furthermore, serum and sputum IL-33 levels were higher in COPD subjects with sputum eosinophilia than in those with a sputum eosinophil count ≤3% (p < 0.001 for both). | 29859068 | 2018 | ||||
|
0.080 | Biomarker | group | BEFREE | While treatment of asthmatic patients with the GATA3-specific DNAzyme SB010 attenuated sputum eosinophilia after allergen challenge, this specific treatment has not been evaluated in patients with COPD. | 29615049 | 2018 | ||||
|
0.080 | Biomarker | group | BEFREE | Eosinophilia was associated with an increased risk of 12-month COPD-related readmission (OR, 3.59 [95% CI, 1.65-7.82]; P = .0013), an increased risk of 12-month all-cause readmission (2.32 [95% CI, 1.10-4.92]; P = .0277), and a shorter time to first COPD-related readmission (hazard ratio, 2.74 [1.56-4.83]; P = .0005). | 27746201 | 2017 | ||||
|
0.080 | Biomarker | group | BEFREE | Blood eosinophilia as a marker of early and late treatment failure in severe acute exacerbations of COPD. | 28947018 | 2017 | ||||
|
0.080 | Biomarker | group | BEFREE | Inflammatory biomarkers (exhaled nitric oxide and eosinophilia in sputum or bronchoalveolar lavage fluid) help distinguish asthma from COPD. | 22222125 | 2012 |